These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 8335511)

  • 21. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytotoxicity and uptake of pefloxacin, ciprofloxacin, and ofloxacin in primary cultures of rat hepatocytes.
    Nordmann P; Pechinot A; Kazmierczak A
    J Antimicrob Chemother; 1989 Sep; 24(3):355-63. PubMed ID: 2808191
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Diffusion of fluoroquinolones in the aqueous humor and crystalline lens].
    Lafaix C; Salvanet A; Fisch A; Forestier F; Montay G; Meulemans A
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):768-71. PubMed ID: 3309812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effect of ofloxacin, pefloxacin, and tobramycin on the hydrophobicity of Klebsiella pneumoniae].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1999 Feb; 48(1):28-30. PubMed ID: 11038674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effects of quinolones on human mononuclear leucocyte functions.
    Roche Y; Gougerot-Pocidalo MA; Fay M; Etienne D; Forest N; Pocidalo JJ
    J Antimicrob Chemother; 1987 Jun; 19(6):781-90. PubMed ID: 3497150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of rifampin on the pharmacokinetics of pefloxacin.
    Humbert G; Brumpt I; Montay G; Le Liboux A; Frydman A; Borsa-Lebas F; Moore N
    Clin Pharmacol Ther; 1991 Dec; 50(6):682-7. PubMed ID: 1752112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway?
    Griffiths NM; Hirst BH; Simmons NL
    J Pharmacol Exp Ther; 1994 May; 269(2):496-502. PubMed ID: 8182517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pefloxacin pharmacokinetics in pyo-inflammatory diseases of the kidneys and urinary tract].
    Lopatkin NA; Siniukhin VN; Kondrat'eva EM; Derevianko II
    Antibiot Khimioter; 1991 Nov; 36(11):40-2. PubMed ID: 1793297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steady-state pharmacokinetics of pefloxacin administered once and twice daily.
    Couet W; Lefebvre M; Millerioux L; Mainguy Y; Ingrand I; Fourtillan J
    Chemioterapia; 1987 Jun; 6(2 Suppl):303-4. PubMed ID: 3509423
    [No Abstract]   [Full Text] [Related]  

  • 31. Steady-state kinetics of the quinolone derivatives ofloxacin, enoxacin, ciprofloxacin and pefloxacin during maintenance treatment with theophylline.
    Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL
    Drugs; 1987; 34 Suppl 1():159-69. PubMed ID: 3481317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of pefloxacin in human prostatic tissue.
    Salpigides G; Pangalis A; Kouvelas D; Paradelis AG
    J Chemother; 1995 Nov; 7 Suppl 4():105-6. PubMed ID: 8904124
    [No Abstract]   [Full Text] [Related]  

  • 33. Pefloxacin as a surrogate marker for quinolone susceptibility in
    Sharma P; Dahiya S; Kumari B; Balaji V; Sood S; Das BK; Kapil A
    Indian J Med Res; 2017 May; 145(5):687-692. PubMed ID: 28948961
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparative efficacy and safety of ciprofloxacin, ofloxacin, and pefloxacin in treatment of respiratory infections in children with cystic fibrosis].
    Postnikov SS
    Antibiot Khimioter; 2001; 46(3):16-20. PubMed ID: 11548276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Preclinical pharmacokinetics of pefloxacin].
    Manuĭlov KK; Kashina LB; Iudin SM; Strachunskiĭ LS
    Antibiot Khimioter; 1994 Dec; 39(12):23-6. PubMed ID: 7733782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The in vitro activity of ofloxacin, pefloxacin and ciprofloxacin against various gram negative bacteria isolated from urinary tract infections].
    Tunçkanat F; Yuluğ N
    Mikrobiyol Bul; 1988; 22(3):187-92. PubMed ID: 3252111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinolone therapy of Klebsiella pneumoniae sepsis following irradiation: comparison of pefloxacin, ciprofloxacin, and ofloxacin.
    Brook I; Elliott TB; Ledney GD
    Radiat Res; 1990 May; 122(2):215-7. PubMed ID: 2186431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibacterial activity of ofloxacin and other 4-quinolone derivatives: in-vitro and in-vivo comparison.
    Chantot JF; Bryskier A
    J Antimicrob Chemother; 1985 Oct; 16(4):475-84. PubMed ID: 3864775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Kinetics of pefloxacin diffusion in human bone tissue following a single infusion of 800 mg. Evaluation of an extraction technic using chloroform].
    Etesse-Carsenti H; Garraffo R; Giaume F; Barbarin A; Bernard E; Lapalus P; Argenson C; Drugeon HB; Dellamonica P
    Pathol Biol (Paris); 1988 Jun; 36(5 Pt 2):715-8. PubMed ID: 3054753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of ofloxacin and pefloxacin on human lymphocyte immunoglobulin secretion and on polymorphonuclear leucocyte superoxide anion production.
    Fantoni M; Tamburrini E; Pallavicini F; Antinori A; Nervo P
    J Antimicrob Chemother; 1988 Aug; 22(2):193-6. PubMed ID: 2846490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.